UnknownNot Applicable

The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma

China148 participantsStarted 2023-06-01

Plain-language summary

The clinical trial was designed to determine the efficacy (sensitivity and specificity) of the IUrisure test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of urothelial carcinoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with high suspicion/confirmed urothelial carcinoma by CT, CTU, MR and other imaging examinations and meet the indications for surgery, including TURbt, partial cystectomy, radical nephroperectomy and kidney-sparing surgery;
✓. Patients with highly suspected/confirmed recurrence of urothelial carcinoma who meet the indications for surgery, including TURbt, partial cystectomy, radical nephroperectomy and kidney-sparing surgery;
✓. The patient agrees to participate in this study and has signed the informed consent form.

What they're measuring

Specificity of IUrisure test

Timeframe: Day 1

Sensitivity of IUrisure test

Timeframe: Day 1

Trial details

NCT IDNCT06564363

SponsorWuhan Ammunition Life-tech Co., Ltd

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-09-30

Contact for this trial

Xuesong Li

15801399116 pineneedle@sina.com

View on ClinicalTrials.gov More Urothelial Carcinoma trials